Transverse myelitis: a complication of systemic lupus erythematosus that is associated with the antiphospholipid syndrome. by Smyth, A. E. et al.
The Ulster Medical Journal, Volume 65, No. 1, pp. 91-94, May 1996.
Case Report
Transverse myelitis: a complication of systemic lupus
erythematosus that is associated with the antiphospholipid
syndrome
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WereportacaseofapatientwithSystemic Lupus
Erythematosus (SLE) complicated by the
antiphospholipid syndrome and recurrent
episodes of transverse myelitis. Transverse
myelitis is a rare complication of SLE and most
cases are associated with the presence of an
antiphospholipid antibody (APA). Thepathogenic
mechanismoftransverse myelitis inthiscondition
may result from a vasculitic process. However,
theassociationwithanAPAsuggestsathrombotic
causation, hence consideration should be given
toanticoagulanttherapy inadditiontoestablished
immunosuppressive treatment. This case also
illustratesthevalueofrecentlydevelopedenzyme
linked immunosorbent assays for measuring
anticardiolipin antibodies overprevious methods
available in Belfastparticularly those employing
the VDRL cardiolipin as antigen.
CASEREPORT. A58yearoldCaucasian woman
presented to the Rheumatology Unit with a 3 day
history ofprogressive weakness andnumbness in
her legs, vague lower back pain and urinary
incontinence. A diagnosis of systemic lupus
erythematosus (SLE) hadbeenmadetwelveyears
previously on the basis of arthritis, pleurisy, a
"butterfly" facial rash and a positive antinuclear
antibody. She described three similar episodes
requiring hospital admission during the previous
three years. On each occasion she had received
oral corticosteroids, with gradual, albeit
incomplete, improvement in her clinical
condition. Examination showed severeweakness
ofthe left lower limb and moderate weakness on
the right in a pyramidal pattern. There was a
sensory level to pinprick sensation below T8 on
the right side and impaired posterior column
sensation on the left. Deep tendon reflexes were
increasedinthelowerlimbswithbilateralextensor
plantar responses. The cranial nerves and upper
limbs were normal. These signs suggested an
incomplete spinal cord lesion in the region ofT8.
Initial investigations were as follows:
ESR 45mm/hr (Westergren); Full blood picture
normal; C-reactive protein (CRP) 6mg/1 (normal
range < 1 Omg/i); Renal function normal;
Antinuclear antibody IgG 160, IgM 80;
antinucleolar antibody IgG 320, IgM negative;
antibody to double stranded DNA 6.6 (normal
range 0-Smg/l); antibodies to Ro, La and Sm
were all positive; pANCA 80, anti-
myeloperoxidase antibodies negative;
immunoglobulins, C3, C4 and CH50 were all
within the normal range with no circulating
immune complexes detected. Antibody to
anticardiolipin (VDRLAntigen) wasnegative on
repeated testing. The ELISA test for
anticardiolipin (aCL) was, retrospectively
performed on 7 serum samples stored during the
previous 2 years, with aCL IgG elevated on 2 of
these occasions at levels of 24.2 and 32.7 GPL
units/mL (normal range < 23) and aCL IgM
elevated on one occasion at a level of 13.5 MPL
units/mL (normalrange<I 1). Visual and sensory
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evoked responses were all normal. Magnetic
resonance imaging (MRI) ofthe dorsal spine and
brainshowednospinalabnormalitybutmultifocal
cerebral infarctions were reported as being
suggestive of vasculitis. Cerebrospinal fluid
examinationrevealedonlyamoderatelyincreased
protein level (0.64mg/1) with remaining
parameters being normal. CT myelogram
performed during a previous hospital admission
wasnormal. Echocardiogramshowednoevidence
of endocarditis. A diagnosis of recurrent
transverse myelitis complicating SLE was made
and treatment was commenced with pulsed




achange in herimmunosuppressive regime from
cyclophosphamide to methotrexate. There was
littleimprovementinhercondition oneitherdrug
andacourseofintravenous immunoglobulin was
therefore introduced with some benefit. Prior to
discharge she was commenced on maintenance
oral therapy withcyclophosphamide 100mg/day
and prednisolone 15mg/day.
Nine weeks from her initial presentation she
developed a deep venous thrombosis in her left
legdespiteroutineheparinprophylaxis of 12,500
IU given daily by subcutaneous injection,
following which she was commenced on long
term warfarin therapy maintaining the
international normalised ratio (INR) at a level
greater than 3.0. Eleven months after initial
presentation to our unit she had grade 3/5 power
oftherighthipflexors andgrade4/5poweronthe
left. She continued to have regular outpatient
physiotherapy.
DISCUSSION
Neuropsychiatric manifestations ofSLE occurin
up to 50% of patients, ranking only second to
renal complications as the leading cause ofdeath
in SLE.1 Transverse myelitis is uncommon,
occurring in less than 1% of patients and is
generally associated with apoorprognosis.2 The
myelopathy usually presents acutely with
paraethesia in the legs, ascending to the thorax
within 24-48 hours. Other consistent features
includeparaplegia,backpainandlossofsphincter
control.3 In SLE the occurrence of transverse
myelitis is strongly associated with the presence
of elevated levels of antiphospholipid antibody
(APA). In one large study 12 patients with SLE
foundtohavetransverse myelitis wereallpositive
for anticardiolipin antibody.4 It is of note that
patients with the clinically similar Jamaican
myelopathy frequentlyhavechronicfalsepositive
tests for syphilis.5 The diagnosis of transverse
myelitis was initially made on clinical grounds
aidedby serologicaltests andimaging modalities
primarily aimed at excluding other pathology.
The value of CSF examination is controversial
but abnormalities reported include elevated
protein, pleocytosis, lowC4, lowglucose, altered
immunoglobulin concentration and immune
complexes.6 MRI is the procedure of choice for
detecting lesions of the spinal cord and several
case reports have shown abnormal signals at the
level of the patients' tranverse myelitis. This
suggests it may have an additional role in the
diagnosisoftransversemyelitisandinmonitoring
the response to treatment.2'7
The antiphospholipid syndrome (APS) was
initially described in SLE patients as a triad of
venous or arterial thrombosis, recurrent foetal
loss and thrombocytopenia associated with the
presence of an antiphospholipid antibody8
(Table 1). Since the original description further
clinical manifestations have been found to
correlatewithelevatedantiphospholipidantibody
levels in SLE 9 (Table2). Ithas alsobecomeclear
that 'primary' antiphospholipid syndrome can
alsooccurintheabsenceofclinicalorserological
evidence of SLE.10
There are three main ways of detecting APA in
serumorplasma.IIThefirstconsistsofserological
tests used in the diagnosis of syphilis, as the
antigenic materialusedintheVDRLtestcontains
the anionic phospholipid cardiolipin. This
performs poorly in screening for APS and was
negative on several occasions in our patient. The
secondisthelupus anticoagulant test(LA) which
is detected as a paradoxical prolongation of the
partial thromboplastin time that cannot be
correctedbytheadditionofnormalhumanplasma
in vitro. It has been shown to be mediated by
antibodies which bind to anionic phospholipids.
The LA test was not determined in our patient as
prophylactic heparin had been commenced from
thetimeofadmissionandthetestwouldtherefore
have been invalid. Finally, an enzyme linked
immunosorbent assay (ELISA) has been
developed to measure anticardiolipin antibody
levels (aCL) directed against the cardiolipin
diphosphatidyl glycerol from calfheart. This has
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TABLE 1
Original Diagnostic Criteria For The Antiphospholipid Syndrome
(after GRVHughes et al Reference 8)
Clinical Features Laboratory
Venous thrombosis 1gG aCL (elevated levels)
Arterial thrombosis 1gM aCL (elevated levels)
Recurrent foetal loss Positive LA test
Thrombocytopenia
Patients with the syndrome required at least one clinical plus one laboratory finding during their disease. The laboratory
test must be positive on at least two occasions.
several benefits in that it can be used on banked
frozen sera, anticoagulants do not affect results
and identification and quantification ofdifferent
aCL isotypes is possible. The ELISA is more
sensitive at detecting aCL, thus manyregard it as
themostclinicallyusefulscreeningtest. However,
the LA test appears to be more specific for
predicting clinical features other than transverse
myelitis which has not been formally tested.
Unfortunately, the ELISA test was not available
inBelfastduringthispatient' sinitialpresentation
and the elevated aCL was detected on banked
frozen sera 2 years later. Sera from 94 healthy
blood donors have been tested by the Sigma
immunoassay currently usedinBelfast; themean
+2 SD (standarddeviation) values obtainedwere
12 + 10.6 GPLunits/mL forIgG and5 + 5.6 MPL
units/mLforIgM.ThefrequencyofaCLpositivity
in SLE patients ranges from 17-61%."1 In a series
of 95 Irish patients it was found to be 44%*.12
The pathogenic mechanisms underlying
transverse myelitis are unknown, although
vasculitis and ischaemia have been described at
postmortemexamination.6"3 Thealmostuniversal
finding of antiphospholipid antibodies in such
patients can be interpreted in different ways; for
instance APA might simply result from
inflammatory vascular damage. There is,
however, good evidence that they contribute
directly to a procoagulant state5 so that vascular
occlusive myelitis secondary to thrombosis must
beconsidered. Finally directinteractionbetween
APAandspinalcordphospholipidsinthepresence
of a co-factor, a B-2 glycoprotein I has been
postulated.5 14 In our patient, vasculitis should
not be assumed on the basis ofthe cerebral MRI
findings, since similar appearances have been
reported in primary APA syndrome9 and in
addition she had no clinical features to suggest
widespread lupus vasculitis.
The treatment regimes available include high
dose steroids and immunosuppressive agents,
which suppress the autoimmune response and
inflammation involved in the vasculitic process.
The value of isolated cases reported as showing
improvement with plasma exchange and
hydroxychloroquine have yet to be validated. In
summary, this case emphasises the need to test
for antiphospholipid antibodies, ideally by all
three methods, in all patients presenting with
transverse myelitis whether known to have SLE
or not. As antibody levels vary with time and
disease activity repeated measurements are
advised.9 While consensus has yet to be reached
on some aspects of treatment in the APS it is
accepted that those individuals with elevated
APAandahistoryofpreviousthrombosisrequire
long term anticoagulation with warfarin.'4 15
Recent evidence suggests that maintenance of
the INR at greater than 3.0 is required for
secondary prevention of thrombosis in this
condition.'6
While continuation of traditional treatment
regimes for transverse myelitis are appropriate
the presence ofan elevated APA should alert the
clinician to the possible thrombotic mechanism,
andthe needforthepromptinitiation ofadequate
anticoagulation.
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TABLE II
Clinical Manifestations in SLE andAnticardiolipin Status.
(afterAlarcon-Segovia et al Reference 9)
Clinical manifestation Number ofpatients with % with positive aCL
Liovedo reticularis 162 62
Thrombocytopenia 88 66
Recurrent foetal loss 43 60
Venous thrombosis 36 83
Haemolytic anaemia 25 72
Arterial occlusion 16 62
Leg ulcer 15 87
Pulmonary hypertension 5 80
Transverse myelitis 4 100
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